Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P100
Near historical high
vs 2Y Ago
7.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 521.43% |
| Q2 2025 | 55.56% |
| Q1 2025 | -35.71% |
| Q4 2024 | -30.86% |
| Q3 2024 | -22.86% |
| Q2 2024 | 138.64% |
| Q1 2024 | 83.33% |
| Q4 2023 | -95.86% |
| Q3 2023 | 71.09% |
| Q2 2023 | -40.73% |
| Q1 2023 | -51.36% |
| Q4 2022 | -16.83% |
| Q3 2022 | -86.16% |
| Q2 2022 | 4.88% |
| Q1 2022 | -6.84% |
| Q4 2021 | 48.72% |
| Q3 2021 | -41.66% |
| Q2 2021 | 48.96% |
| Q1 2021 | -33.08% |
| Q4 2020 | -11.76% |
| Q3 2020 | -0.66% |
| Q2 2020 | -18.01% |
| Q1 2020 | -18.65% |
| Q4 2019 | -7.23% |
| Q3 2019 | -13.45% |
| Q2 2019 | -2.44% |
| Q1 2019 | 17.60% |
| Q4 2018 | 4.43% |
| Q3 2018 | -3.38% |
| Q2 2018 | 3.43% |
| Q1 2018 | -11.72% |
| Q4 2017 | 16.97% |
| Q3 2017 | 0.00% |